Last reviewed · How we verify
Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium is a Triple-combination inhaler (ICS/LABA/LAMA) Small molecule drug developed by Chiesi Farmaceutici S.p.A.. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Asthma maintenance therapy (in select populations). Also known as: CHF5993 pMDI.
This triple-combination inhaler delivers a corticosteroid to reduce airway inflammation, a long-acting beta-2 agonist to relax airway smooth muscle, and an anticholinergic to further dilate airways.
This triple-combination inhaler delivers a corticosteroid to reduce airway inflammation, a long-acting beta-2 agonist to relax airway smooth muscle, and an anticholinergic to further dilate airways. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Asthma maintenance therapy (in select populations).
At a glance
| Generic name | Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium |
|---|---|
| Also known as | CHF5993 pMDI |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Triple-combination inhaler (ICS/LABA/LAMA) |
| Target | Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Beclometasone dipropionate is an inhaled corticosteroid that suppresses airway inflammation and immune responses. Formoterol fumarate is a long-acting beta-2 agonist that bronchodilates by relaxing smooth muscle. Glycopyrronium is a long-acting muscarinic antagonist (anticholinergic) that provides additional bronchodilation by blocking parasympathetic signaling. Together, these three agents provide complementary anti-inflammatory and bronchodilatory effects for maintenance therapy in obstructive airway disease.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Asthma maintenance therapy (in select populations)
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Oral candidiasis
- Muscle cramps
Key clinical trials
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
- Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (PHASE3)
- Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma (PHASE2)
- Immuno-inflammatory Response of Erdosteine in COPD (NA)
- Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium CI brief — competitive landscape report
- Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI
Frequently asked questions about Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
What is Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium?
How does Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium work?
What is Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium used for?
Who makes Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium?
Is Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium also known as anything else?
What drug class is Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium in?
What development phase is Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium in?
What are the side effects of Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium?
What does Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium target?
Related
- Drug class: All Triple-combination inhaler (ICS/LABA/LAMA) drugs
- Target: All drugs targeting Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
- Manufacturer: Chiesi Farmaceutici S.p.A. — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Indication: Drugs for Asthma maintenance therapy (in select populations)
- Also known as: CHF5993 pMDI
- Compare: Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium vs similar drugs
- Pricing: Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium cost, discount & access